Cargando…

Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting

BACKGROUND: Small cell lung cancer (SCLC) represents approximately 13 to 18% of all lung cancers. It is the most aggressive among lung cancers, mostly presented at an advanced stage, with median survival rates of 10 to12 months in patients treated with standard chemotherapy and radiotherapy. In appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lekic, Mirko, Kovac, Viljem, Triller, Nadja, Knez, Lea, Sadikov, Aleksander, Cufer, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423766/ https://www.ncbi.nlm.nih.gov/pubmed/22933980 http://dx.doi.org/10.2478/v10019-012-0007-1

Ejemplares similares

High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients
por: Koren, Ana, et al.
Publicado: (2017)

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
por: Stanic, Karmen, et al.
Publicado: (2014)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
por: Sodja, Eva, et al.
Publicado: (2016)

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
por: Kukec, Renata Rezonja, et al.
Publicado: (2015)

Oral treatment with etoposide in small cell lung cancer – dilemmas and solutions
por: Rezonja, Renata, et al.
Publicado: (2013)

Real-life Long-term Outcomes of Upfront Surgery in Patients with Resectable Stage I-IIIA Non-small Cell Lung Cancer
por: Bitenc, Marko, et al.
Publicado: (2022)

Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer
por: Koren, Ana, et al.
Publicado: (2021)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Low radiotherapy dose is suitable for brain metastases in SCLC compared with high dose
por: Xu, Liming, et al.
Publicado: (2023)

Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana
por: Stanic, Karmen, et al.
Publicado: (2010)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)

Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial
por: Vrankar, Martina, et al.
Publicado: (2014)

Organoids as a Systems Platform for SCLC Brain Metastasis
por: Quaranta, Vito, et al.
Publicado: (2022)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort
por: Conen, Katrin, et al.
Publicado: (2016)

Small Cell Lung Cancer (SCLC) Presenting as Acute Pancreatitis: The Role of Hypercalcemia
por: Tan, Jessica, et al.
Publicado: (2012)

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes
por: Bebber, Christina M., et al.
Publicado: (2021)

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
por: Oronsky, Bryan, et al.
Publicado: (2022)

Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).
por: Jørgensen, L. G., et al.
Publicado: (1994)

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
por: Men, Yu, et al.
Publicado: (2017)

SCLC-J1, a novel small cell lung cancer cell line
por: Ohara, Kazuo, et al.
Publicado: (2021)

Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)
por: Ding, Xiao-Long, et al.
Publicado: (2022)

Comparison of whole brain radiation therapy for synchronous brain metastases with irradiation protecting the hippocampus versus whole brain radiotherapy for sequential brain metastases to boost irradiation in the treatment of brain metastases from SCLC: study protocol for a randomized controlled trial
por: Zhang, Xiaofang, et al.
Publicado: (2022)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study
por: Ni, Meng, et al.
Publicado: (2020)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
por: Omersa, Daniel, et al.
Publicado: (2016)

Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice
por: Richards, Donald, et al.
Publicado: (2015)

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models
por: Salgia, Ravi, et al.
Publicado: (2018)

Tracheal polypoid combined small cell lung cancer (C‐SCLC): A case report
por: Testori, Alberto, et al.
Publicado: (2021)

Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring
por: Barchiesi, Vittoria, et al.
Publicado: (2021)

An in silico comparative transcriptome analysis identifying hub lncRNAs and mRNAs in brain metastatic small cell lung cancer (SCLC)
por: Mikaeili Namini, Arsham, et al.
Publicado: (2022)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023)

Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
por: Deneka, Alexander Y., et al.
Publicado: (2019)

Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients
por: von Eiff, Damian, et al.
Publicado: (2020)

Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)
por: Bebber, Christina M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2e015qdm8u7j1trftarakm666t